`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________________
`
`BRECKENRIDGE PHARMACEUTICAL, INC., AND
`WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED
`Petitioners,
`
`v.
`
`NOVARTIS AG
`Patent Owner
`_______________________
`Case IPR2017-015921
`Patent US 8,410,131 B2
`_______________________
`
`
`PETITIONER’S UPDATED MANDATORY NOTICE
`PURSUANT TO 37 C.F.R. § 42.8(b)(1)
`
`
`
`
`1 IPR2018-00507 has been joined to this proceeding.
`
`
`
`Case IPR2017-01592
`U.S. Patent No. 8,410,131
`
`
`West-Ward Pharmaceuticals International Limited (“West-Ward”) filed an
`
`IPR Petition on January 17, 2018, along with a Motion for Joinder with
`
`IPR2017-01592. West-Ward was joined as a party in IPR2017-01592 on April 3,
`
`2018. At page 4 of West-Ward’s Petition, in an abundance of caution, West-Ward
`
`identified the entities West-Ward Pharmaceuticals Corp. and Hikma
`
`Pharmaceuticals PLC as additional parties-in-interest.
`
`West-Ward Pharmaceuticals Corp. has changed its name to Hikma
`
`Pharmaceuticals USA Inc. Accordingly, pursuant to 37 C.F.R. § 42.8(b)(1),
`
`West-Ward, in an abundance of caution, identifies Hikma Pharmaceuticals USA
`
`Inc. as an additional entity that is a real-party-in-interest who, going forward, may
`
`have control over this proceeding.
`
`
`
`Dated: July 11, 2018
`
`
`
`
`
`Respectfully submitted,
`
`By: /Marta E. Delsignore/
`Marta E. Delsignore (Reg. No. 32,689)
`
`Counsel for Petitioner West-Ward
`Pharmaceuticals International Limited
`
`1
`
`
`
`Case IPR2017-01592
`U.S. Patent No. 8,410,131
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 11th day of July, 2018,
`
`a true and correct copy of the foregoing PETITIONER’S UPDATED
`
`MANDATORY NOTICE PURSUANT TO 37 C.F.R. § 42.8(b)(1) was served
`
`by electronic mail on Patent Owner’s lead and backup counsel at the following
`
`email addresses:
`
`Nicholas N. Kallas
`Laura K. Fishwick
`Charlotte Jacobsen
`Fitzpatrick, Cella, Harper & Scinto
`nkallas@fchs.com
`lfishwick@fchs.com
`cjacobsen@fchs.com
`ZortressAfinitorIPR@fchs.com
`
`
`
`
`
`
`
`
`
`
`and on Counsel for Petitioner Breckenridge Pharmaceutical, Inc. at the following
`
`email addresses:
`
`Daniel R. Evans
`Melissa M. Hayworth
`Jeffrey D. Blake
`Merchant & Gould P.C.
`devans@merchantgould.com
`mhayworth@merchantgould.com
`jblake@merchantgould.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2017-01592
`U.S. Patent No. 8,410,131
`
`By: /Marta E. Delsignore/
`
`Marta E. Delsignore (Reg. No. 32,689)
`GOODWIN PROCTER LLP
`620 Eighth Avenue
`New York, NY 10018
`212-813-8822
`mdelsignore@goodwinlaw.com
`
`Counsel for Petitioner West-Ward
`Pharmaceuticals International Limited
`
`3
`
`